Journal
BLOOD
Volume 115, Issue 3, Pages 453-474Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-07-235358
Keywords
-
Categories
Funding
- European Union [LSHC-CT-2004-503216]
Ask authors/readers for more resources
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed. (Blood. 2010; 115: 453-474)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available